Table 2.

Treatment description

Pt	Sex	Age	Histology	Prev Rx	Regimens	Rx	Doses	Rx duration (months)
1	M	4	Classic	1	ACNS0331	BIT	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2weeks IV TMZ 200 mg/m2 × 5 days qMo	6
2	M	6	LCA	1	ACNS0332	BIT	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2weeks IV TMZ 200 mg/m2 × 5 days qMo	14a
3	M	2	LCA	3	ACNS0334 CSI  Cis-retinoic acid	BIT	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2weeks IV TMZ 135 mg/m2 × 5 days qMo	15b
4	F	2	Desmo	2	ACNS0334 4  drug metronome	BIT	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2 weeks IV TMZ 100 mg/m2 × 5 days qMo	11
5	M	7	LCA	3	ACNS0331 ICE  4 drug metronome	BI	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2 weeks IV	6
6	F	4	LCA	1	CCG99701	BIT	BV 10 mg/kg q2W IV IRI 125–150 mg/m2  q2weeks IV TMZ 150 mg/m2 × 5 days qMo	55b
7	M	2	Classic	1	CCG99701	BI	BV 10 mg/kg q2weeks IV IRI 125 mg/m2  q2 weeks IV	18
8	F	6	Classic	1	ACNS0331	BITV	BV 10 mg/kg q2weeks IV IRI 90 mg/m2 × 5 days  PO q3 weeks TMZ 100 mg/m2 × 5 days qMo  Vincristine 1.5 mg/m2	10
9	M	6	Classic	1	CCG-A9961	BITV	BV 10 mg/kg q2weeks IV IRI 90 mg/m2 × 5 days  PO q3 weeks TMZ 100 mg/m2 × 5 days qMo  Vincristine 1.5 mg/m2	4

Pt patient number, Prev previous, Rx treatment, M male, F female, qMo every month, IV intravenous, PO oral, LCA large cell/anaplastic, Desmo desmoplastic, BI bevacizumab+irinotecan, BIT BI+temozolomide, BITV BIT+vincristine, BV bevacizumab, IRI irinotecan, TMZ temozolomide, CSI craniospinal irradiation, ICE ifosfamide+carboplatinum+etoposide

^aAlive with disease progression

^bAlive and progression-free